HEPATITIS B - AN OVERVIEW

Pick other brokers are proposed as option brokers determined by administration issues and/or adverse outcome profile.  Zidovudine combined with lamivudine is the alternative NRTI backbone but is connected to a lot more hematologic toxicity. Lopinavir/ritonavir is another PI agent with proven safety but reveals greater gastrointestinal intolerance.